Related Experiment Video
Updated: Jul 18, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Cost-effectiveness as an outcome in randomized clinical trials
Mark A Hlatky1, Douglas K Owens, Gillian D Sanders
1Stanford University School of Medicine, Stanford, CA 94305-5405, USA. hlatky@stanford.edu
Clinical Trials (London, England)
|December 16, 2006
Summary
Incorporating economic outcomes in clinical trials is feasible, though challenges exist in measuring costs from unplanned events. Cost-effectiveness analysis, using models to project long-term benefits, helps determine if new therapies offer value.
Area of Science:
- Health Economics
- Clinical Trial Methodology
- Evidence-Based Medicine
Background:
- Economic outcomes are increasingly integrated into randomized trials to assess interventions.
- Collecting and analyzing economic data in clinical trials presents significant methodological challenges.
Purpose of the Study:
- To review methods for incorporating economic outcomes within clinical trials.
- To guide researchers in the economic evaluation of medical interventions.
Main Methods:
- Review of existing methodologies for economic data collection in clinical trials.
- Discussion of cost measurement, including planned and unplanned clinical events.
- Explanation of cost-effectiveness analysis and its application.
Main Results:
- Economic data, such as medical resource utilization and costs, can be collected concurrently with clinical outcomes.
- Accurate measurement of costs associated with unplanned adverse events remains challenging.
- Cost-effectiveness analysis, often requiring modeling to extrapolate long-term benefits (e.g., quality-adjusted life-years), is crucial for assessing the value of new, often more expensive, therapies.
Conclusions:
- Economic outcomes can be successfully measured alongside clinical outcomes in randomized trials.
- Cost-effectiveness models, while extending beyond empirical within-trial analysis, offer a structured approach to evaluate the worth of interventions.
- These models are essential for determining if clinical improvements justify additional healthcare expenditures.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...